Direito brasileiro da concorrência e acesso à saúde no Brasil: preços exploratórios no setor de medicamentos
This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case law of the Brazilian Administrative Council for Eco...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | Portuguese |
| Veröffentlicht: |
Genebra, Suíça
South Centre
[2022]
|
| Schriftenreihe: | Research paper / South Centre
143 (11 de janeiro de 2022) |
| Schlagworte: | |
| Online-Zugang: | 10419/262116 kostenfrei kostenfrei kostenfrei |
| Zusammenfassung: | This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case law of the Brazilian Administrative Council for Economic Defense (CADE) in the medicines sector and discusses the abuses aiming at the illegitimate imposition of non-existent or invalid intellectual property rights with anticompetitive purposes. It then addresses the abuses in the exercise of industrial property rights that are, in themselves, valid: exclusionary practices aimed at artificially raising barriers to entry, and exploitative practices, directly translated into the exercise of market power to the detriment of the consumer. The latter are turned into exploitative excessive prices, contractual degradations, quality or privacy degradations, as well as restrictions on supply such as hoarding/impediment to the exploitation of industrial property rights. The paper concludes that the prohibition of exploitative pricing under the current competition law is legally valid and effective, with certain methodological concerns in order to minimize the risk of wrongful convictions (such as the construction of "screening" tests of markets that are candidates for intervention). In view of such guidelines, the pharmaceutical industry appears to be an important candidate for antitrust attention, given the magnitude of the damages potentially derived from the non-intervention on the practice. Remedies in this area, importantly, should focus on identifying and solving the sector’s structural competitive problems. In the case of drugs subject to price regulation by the Drugs Market Regulation Chamber (CMED), the technical expertise of the competition authority may be of great value in competition advocacy, which is demonstrated in light of the recent discussions about extraordinary price adjustments due to competitive problems in a given market. |
| Beschreibung: | 1 Online-Ressource (ca. 58 Seiten) |
Internformat
MARC
| LEADER | 00000nmm a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV049026943 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 230629s2022 sz |||| o||u| ||||||por d | ||
| 035 | |a (DE-599)KXP1786048671 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a por | |
| 044 | |a sz |c XA-CH | ||
| 049 | |a DE-M382 | ||
| 100 | 1 | |a Castro, Bruno Braz de |e Verfasser |0 (DE-588)1254066802 |4 aut | |
| 245 | 1 | 0 | |a Direito brasileiro da concorrência e acesso à saúde no Brasil |b preços exploratórios no setor de medicamentos |c Bruno Braz de Castro |
| 264 | 1 | |a Genebra, Suíça |b South Centre |c [2022] | |
| 300 | |a 1 Online-Ressource (ca. 58 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Research paper / South Centre |v 143 (11 de janeiro de 2022) | |
| 520 | 3 | |a This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case law of the Brazilian Administrative Council for Economic Defense (CADE) in the medicines sector and discusses the abuses aiming at the illegitimate imposition of non-existent or invalid intellectual property rights with anticompetitive purposes. It then addresses the abuses in the exercise of industrial property rights that are, in themselves, valid: exclusionary practices aimed at artificially raising barriers to entry, and exploitative practices, directly translated into the exercise of market power to the detriment of the consumer. | |
| 520 | 3 | |a The latter are turned into exploitative excessive prices, contractual degradations, quality or privacy degradations, as well as restrictions on supply such as hoarding/impediment to the exploitation of industrial property rights. The paper concludes that the prohibition of exploitative pricing under the current competition law is legally valid and effective, with certain methodological concerns in order to minimize the risk of wrongful convictions (such as the construction of "screening" tests of markets that are candidates for intervention). In view of such guidelines, the pharmaceutical industry appears to be an important candidate for antitrust attention, given the magnitude of the damages potentially derived from the non-intervention on the practice. Remedies in this area, importantly, should focus on identifying and solving the sector’s structural competitive problems. | |
| 520 | 3 | |a In the case of drugs subject to price regulation by the Drugs Market Regulation Chamber (CMED), the technical expertise of the competition authority may be of great value in competition advocacy, which is demonstrated in light of the recent discussions about extraordinary price adjustments due to competitive problems in a given market. | |
| 546 | |a Zusammenfassung in englischer Sprache | ||
| 653 | 0 | |a Access to Healthcare | |
| 653 | 0 | |a Access to Medicines | |
| 653 | 0 | |a Antitrust | |
| 653 | 0 | |a Brazil | |
| 653 | 0 | |a Competition | |
| 653 | 0 | |a Competition Law | |
| 653 | 0 | |a Competition Policy | |
| 653 | 0 | |a Competition Regulation | |
| 653 | 0 | |a COVID-19 | |
| 653 | 0 | |a Health | |
| 653 | 0 | |a Industrial Property | |
| 653 | 0 | |a Industrial Property Rights | |
| 653 | 0 | |a Intellectual Property | |
| 653 | 0 | |a Intellectual Property Rights (IPRs) | |
| 653 | 0 | |a Pandemic | |
| 653 | 0 | |a Pharmaceuticals | |
| 653 | 6 | |a Graue Literatur | |
| 856 | |u 10419/262116 | ||
| 856 | 4 | 0 | |u https://www.southcentre.int/wp-content/uploads/2022/01/RP-143.pdf |x Verlag |z kostenfrei |
| 856 | 4 | 0 | |u https://www.southcentre.int/research-paper-143-11-de-janeiro-de-2022/ |x Verlag |z kostenfrei |
| 856 | 4 | 0 | |u http://hdl.handle.net/10419/262116 |x Resolving-System |z kostenfrei |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034289726 | ||
Datensatz im Suchindex
| _version_ | 1804185308337537024 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Castro, Bruno Braz de |
| author_GND | (DE-588)1254066802 |
| author_facet | Castro, Bruno Braz de |
| author_role | aut |
| author_sort | Castro, Bruno Braz de |
| author_variant | b b d c bbd bbdc |
| building | Verbundindex |
| bvnumber | BV049026943 |
| ctrlnum | (DE-599)KXP1786048671 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03871nmm a2200553 cb4500</leader><controlfield tag="001">BV049026943</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">230629s2022 sz |||| o||u| ||||||por d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KXP1786048671</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">por</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">sz</subfield><subfield code="c">XA-CH</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M382</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Castro, Bruno Braz de</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1254066802</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Direito brasileiro da concorrência e acesso à saúde no Brasil</subfield><subfield code="b">preços exploratórios no setor de medicamentos</subfield><subfield code="c">Bruno Braz de Castro</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Genebra, Suíça</subfield><subfield code="b">South Centre</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (ca. 58 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Research paper / South Centre</subfield><subfield code="v">143 (11 de janeiro de 2022)</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case law of the Brazilian Administrative Council for Economic Defense (CADE) in the medicines sector and discusses the abuses aiming at the illegitimate imposition of non-existent or invalid intellectual property rights with anticompetitive purposes. It then addresses the abuses in the exercise of industrial property rights that are, in themselves, valid: exclusionary practices aimed at artificially raising barriers to entry, and exploitative practices, directly translated into the exercise of market power to the detriment of the consumer. </subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">The latter are turned into exploitative excessive prices, contractual degradations, quality or privacy degradations, as well as restrictions on supply such as hoarding/impediment to the exploitation of industrial property rights. The paper concludes that the prohibition of exploitative pricing under the current competition law is legally valid and effective, with certain methodological concerns in order to minimize the risk of wrongful convictions (such as the construction of "screening" tests of markets that are candidates for intervention). In view of such guidelines, the pharmaceutical industry appears to be an important candidate for antitrust attention, given the magnitude of the damages potentially derived from the non-intervention on the practice. Remedies in this area, importantly, should focus on identifying and solving the sector’s structural competitive problems. </subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">In the case of drugs subject to price regulation by the Drugs Market Regulation Chamber (CMED), the technical expertise of the competition authority may be of great value in competition advocacy, which is demonstrated in light of the recent discussions about extraordinary price adjustments due to competitive problems in a given market.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">Zusammenfassung in englischer Sprache</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Access to Healthcare</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Access to Medicines</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Antitrust</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Brazil</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Competition</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Competition Law</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Competition Policy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Competition Regulation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Health</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Industrial Property</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Industrial Property Rights</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Intellectual Property</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Intellectual Property Rights (IPRs)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pandemic</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmaceuticals</subfield></datafield><datafield tag="653" ind1=" " ind2="6"><subfield code="a">Graue Literatur</subfield></datafield><datafield tag="856" ind1=" " ind2=" "><subfield code="u">10419/262116</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.southcentre.int/wp-content/uploads/2022/01/RP-143.pdf</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.southcentre.int/research-paper-143-11-de-janeiro-de-2022/</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://hdl.handle.net/10419/262116</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034289726</subfield></datafield></record></collection> |
| id | DE-604.BV049026943 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T22:15:20Z |
| indexdate | 2024-07-10T09:53:10Z |
| institution | BVB |
| language | Portuguese |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034289726 |
| open_access_boolean | 1 |
| owner | DE-M382 |
| owner_facet | DE-M382 |
| physical | 1 Online-Ressource (ca. 58 Seiten) |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | South Centre |
| record_format | marc |
| series2 | Research paper / South Centre |
| spelling | Castro, Bruno Braz de Verfasser (DE-588)1254066802 aut Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos Bruno Braz de Castro Genebra, Suíça South Centre [2022] 1 Online-Ressource (ca. 58 Seiten) txt rdacontent c rdamedia cr rdacarrier Research paper / South Centre 143 (11 de janeiro de 2022) This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with special focus on abuses of industrial property rights in their exclusionary and exploitative effects. The paper analyzes the case law of the Brazilian Administrative Council for Economic Defense (CADE) in the medicines sector and discusses the abuses aiming at the illegitimate imposition of non-existent or invalid intellectual property rights with anticompetitive purposes. It then addresses the abuses in the exercise of industrial property rights that are, in themselves, valid: exclusionary practices aimed at artificially raising barriers to entry, and exploitative practices, directly translated into the exercise of market power to the detriment of the consumer. The latter are turned into exploitative excessive prices, contractual degradations, quality or privacy degradations, as well as restrictions on supply such as hoarding/impediment to the exploitation of industrial property rights. The paper concludes that the prohibition of exploitative pricing under the current competition law is legally valid and effective, with certain methodological concerns in order to minimize the risk of wrongful convictions (such as the construction of "screening" tests of markets that are candidates for intervention). In view of such guidelines, the pharmaceutical industry appears to be an important candidate for antitrust attention, given the magnitude of the damages potentially derived from the non-intervention on the practice. Remedies in this area, importantly, should focus on identifying and solving the sector’s structural competitive problems. In the case of drugs subject to price regulation by the Drugs Market Regulation Chamber (CMED), the technical expertise of the competition authority may be of great value in competition advocacy, which is demonstrated in light of the recent discussions about extraordinary price adjustments due to competitive problems in a given market. Zusammenfassung in englischer Sprache Access to Healthcare Access to Medicines Antitrust Brazil Competition Competition Law Competition Policy Competition Regulation COVID-19 Health Industrial Property Industrial Property Rights Intellectual Property Intellectual Property Rights (IPRs) Pandemic Pharmaceuticals Graue Literatur 10419/262116 https://www.southcentre.int/wp-content/uploads/2022/01/RP-143.pdf Verlag kostenfrei https://www.southcentre.int/research-paper-143-11-de-janeiro-de-2022/ Verlag kostenfrei http://hdl.handle.net/10419/262116 Resolving-System kostenfrei |
| spellingShingle | Castro, Bruno Braz de Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos |
| title | Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos |
| title_auth | Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos |
| title_exact_search | Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos |
| title_exact_search_txtP | Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos |
| title_full | Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos Bruno Braz de Castro |
| title_fullStr | Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos Bruno Braz de Castro |
| title_full_unstemmed | Direito brasileiro da concorrência e acesso à saúde no Brasil preços exploratórios no setor de medicamentos Bruno Braz de Castro |
| title_short | Direito brasileiro da concorrência e acesso à saúde no Brasil |
| title_sort | direito brasileiro da concorrencia e acesso a saude no brasil precos exploratorios no setor de medicamentos |
| title_sub | preços exploratórios no setor de medicamentos |
| url | 10419/262116 https://www.southcentre.int/wp-content/uploads/2022/01/RP-143.pdf https://www.southcentre.int/research-paper-143-11-de-janeiro-de-2022/ http://hdl.handle.net/10419/262116 |
| work_keys_str_mv | AT castrobrunobrazde direitobrasileirodaconcorrenciaeacessoasaudenobrasilprecosexploratoriosnosetordemedicamentos |